secwatch.observer — SEC 8-K summary
======================================

Issuer:     Chemours Co (CC)
CIK:        0001627223
Form:       8-K
Filed at:   2026-02-19T23:59:59+00:00
Accession:  0001193125-26-059564
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Chemours Q4 net loss widens to $47M; full year 2026 outlook: Adj. EBITDA $800M-$900M
--------------------------------------------------------------------------------

- Q4 net loss $47M (-$0.31/diluted) vs loss $11M (-$0.08) YoY; adjusted net income $7M ($0.05) vs $14M ($0.09).
- Q4 adjusted EBITDA $128M vs $168M YoY; net sales $1.3B slightly down; TSS segment record Q4 with 37% Opteon revenue growth.
- Full year 2025 net loss $386M (-$2.57/diluted) vs net income $69M ($0.46) prior year; adjusted net income $143M ($0.95) vs $179M ($1.19).
- Full year 2026 outlook: net sales growth 3-5%, adjusted EBITDA $800-$900M, free cash flow conversion above 25%.
- Announced sale of former Kuan Yin TiO2 site for ~$300M net proceeds on Jan 15, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1627223/000119312526059564/0001193125-26-059564-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1627223/000119312526059564/cc-20260219.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-059564

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer